SA LVA G E CRYO ABLATIO N
For Recurrence of Prostate Cancer after Radiation Therapy

Salvage cryoablation continues to demonstrate safety and efficacy.

- Cancer Specific Survival = 84% (10 years)\(^3\)
- COLD Registry results for over 500 patients\(^4\)
  - Biochemical Efficacy = 69% (5 years)
  - Incontinence = 12%
  - Retention = 4%
  - Rectal fistula = 1.5%

AUA Best Practice Statement for Cryoablation\(^5\) concludes that salvage cryoablation is appropriate for men with biopsy-confirmed organ confined disease, ideally with:

- PSA < 10 ng/mL, with optimal candidates having a PSA \(\leq 4\) ng/mL
- Slowly rising PSA
- No evidence of seminal vesicle invasion
- Negative metastatic evaluation
- Life expectancy > 10 years

Salvage cryoablation is a minimally invasive treatment option for biopsy-confirmed local prostate cancer following radiation failure. The procedure can be used on patients following external beam radiation, brachytherapy and combination radiation.

For more information regarding Salvage CryoAblation please contact your HealthTronics representative

(888) 252-6575

\(^2\) Taylor LG, Canfield SE, and Du XL, Cancer 2009; 115:2388-99
\(^3\) Chalmers P et al, J Endourol 2010; 24(7):1123-9

Endocare is a wholly-owned subsidiary of HealthTronics, Inc., Austin, TX 78717